ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

8:30AM-10:30AM: Abstract Number: 1818

Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1826

Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1737

Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1790

Regional Differences in Clinical Characteristics and Treatment of Psoriatic Arthritis with Axial Involvement: Results from the Cross Sectional International ASAS PerSpA Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

8:30AM-10:30AM: Abstract Number: 1584

Relation of Depressive Symptoms to Alterations in Conditioned Pain Modulation in Knee Osteoarthritis: The Multicenter Osteoarthritis Study (MOST)

Orthopedics, Low Back Pain, & Rehabilitation Poster (1584–1588)

8:30AM-10:30AM: Abstract Number: 1588

Relation of Foot and Ankle Pain to Worsening Knee Pain: The MOST Study

Orthopedics, Low Back Pain, & Rehabilitation Poster (1584–1588)

8:30AM-10:30AM: Abstract Number: 1660

Relationship Between Risk of New Onset Diabetes Mellitus and Exposure to Individual Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

8:30AM-10:30AM: Abstract Number: 1822

Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1807

Relationships Between Fatigue and Hemoglobin/C-Reactive Protein Levels and Associations Between Fatigue and Clinical Response in Patients with Active Psoriatic Arthritis: Results from Two Randomized Controlled Trials of Guselkumab (TREMFYA®)

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1628

Reproductive Health Knowledge Gaps, Needs, and Barriers Identified by Pediatric Rheumatology Providers

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1615

Responsiveness of Quality of Life and Function Assessment to Changes in Topical Eye Medications in Children with Uveitis

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1673

Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

8:30AM-10:30AM: Abstract Number: 1525

Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial

Immunological Complications of Therapy Poster (1516–1529)

8:30AM-10:30AM: Abstract Number: 1833

Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1675

Risk of Malignancy in Patients Treated with Tofacitinib: Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study

RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].